// App-Quantinova.ai

PB1764 : HIBISCUS, AN ADAPTIVE, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, MULTICENTER STUDY OF ORAL FT-4202, A PYRUVATE KINASE ACTIVATOR IN PATIENTS WITH SICKLE CELL DISEASE

Researchers

Presenter

  • Kenneth Ataga

Principal Investigators

  • Kenneth Wood

  • James Geib

  • Eric Wu

  • Jason Berlin

  • Irena Webster

  • Jo Howard

  • Jeremie H. Estepp

  • Julie Brevard

  • Marilyn J. Telen

Medical Centers

  • University of Tennessee Health Science Center, Memphis, Tennessee, United States

  • Duke University, Durham, North Carolina, United States

  • Guy's And St Thomas NHS Foundation Trust, London, United Kingdom

  • St Jude Childrens Research Hospital, Memphis, TN, United States

  • FORMA Therapeutics, Inc.,Watertown,United States

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

  • Nephrology

  • Central Nervous System (CNS)

  • Blood/haematological Diseases

Disease

  • Sickle cell anemia

  • Chronic obstructive pulmonary disease

  • Renal insufficiency

  • Stroke

Biomarkers

  • Stearoyl-CoA desaturase

  • Red Blood Cells

  • Volatile organic compounds

Drug/Treatment

  • Hydroxyurea

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Adaptive

  • Double Blind/Blinded

  • Open Label

  • Multicenteric

  • Controlled

Phase

  • II/III

Study Id's

  • NCT03815695

  • NCT04624659

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved